Amphastar Pharmaceuticals, Inc (AMPH)

Currency in USD
29.22
-0.15(-0.51%)
Real-time Data·

AMPH Income Statement

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa-1.56%+10.39%+9.03%+9.28%+14.32%
aa.aaaa.aaaa.aaaa.aaaa.aa60.9374.7773.7473.9185.84
aa.aaaa.aaaa.aaaa.aaaa.aa67.1266.5980.3994.52106.71
aa.aaaa.aaaa.aaaa.aaaa.aa-----
* In Millions of USD (except for per share items)

FAQ

What was Amphastar Pharmaceuticals’s revenue at year end?

At the end of the last reported fiscal year, Amphastar Pharmaceuticals (AMPH) recorded total revenue of 719.89 million USD.

How much revenue did Amphastar Pharmaceuticals report in the most recent quarter?

In its most recent quarterly earnings report, Amphastar Pharmaceuticals posted revenue of 207.61 million USD.

What was Amphastar Pharmaceuticals’s net income for the year?

For the full year, Amphastar Pharmaceuticals reported net income of 98.09 million USD.

How much net income did Amphastar Pharmaceuticals post in the last quarter?

In the most recent quarter, Amphastar Pharmaceuticals (AMPH) posted net income of 37.76 million USD.

What was Amphastar Pharmaceuticals’s gross profit for the year?

Gross profit for the year was reported at 356.06 million USD.

How much gross profit did Amphastar Pharmaceuticals generate last quarter?

Amphastar Pharmaceuticals recorded gross profit of 99.63 million USD in its latest quarterly report.

What was Amphastar Pharmaceuticals’s annual operating income?

For the full year, Amphastar Pharmaceuticals (AMPH) reported operating income of 163.50 million USD.

What was Amphastar Pharmaceuticals’s operating income last quarter?

Quarterly operating income was 50.77 million USD.

What was Amphastar Pharmaceuticals’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at 66.36 million USD.

What was the quarter-over-quarter change in EBITDA for Amphastar Pharmaceuticals?

EBITDA changed by 22.79% million USD compared to the last quarter.

What is Amphastar Pharmaceuticals’s most recent gross profit margin?

The latest reported gross profit margin for Amphastar Pharmaceuticals (AMPH) is 47.99% million USD.

What is Amphastar Pharmaceuticals’s most recent net income margin?

Net income margin based on recent financials is 18.19% million USD.

What is Amphastar Pharmaceuticals’s most recent EBIT margin?

Amphastar Pharmaceuticals reported an EBIT margin of 24.46% million USD based on current figures.

How did Amphastar Pharmaceuticals’s revenue change compared to the previous quarter?

Revenue changed by 12.89% million USD compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Amphastar Pharmaceuticals?

In the latest quarter, gross profit changed by 6.59% million USD from the previous quarter.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.